儿童急性呼吸窘迫综合征表型的潜在类别分析
该研究对RESTORE试验和BALI辅助研究中的304例儿童ARDS患者数据进行二次分析,采用潜在类别分析识别出两种表型:高炎症型(表型2,40%)和低炎症型(表型1,60%)。高炎症型表现为炎症生物标志物更高、血管活性药物使用更多、脓毒症诊断更频繁,且机械通气时间更长、死亡率更高。
要点
- 儿童ARDS存在两种表型,高炎症型占40%,低炎症型占60%。
核心结论
- 儿童ARDS可识别出与成人相似的高炎症型和低炎症型两种表型,高炎症型临床结局更差。
- 建议在未来儿童临床试验的设计和分析中考虑PARDS表型。
研究设计与样本
- 研究为二次分析,数据来自RESTORE临床试验和BALI辅助研究。
- 纳入304例儿童PARDS患者,采用潜在类别分析,纳入人口学、临床和血浆生物标志物变量。
主要发现
- 两类别模型优于单类别模型(p<0·001)。
- 表型1为181例(60%),表型2为123例(40%)。
- 表型2炎症生物标志物浓度更高、血管活性药物使用率更高、脓毒症诊断更频繁。
- 表型2机械通气中位时间10·0天(IQR 6·3-21·0),表型1为6·6天(IQR 4·1-10·8),p<0·0001。
- 表型2死亡率13·8%(17/123),表型1为2·2%(4/181),p=0·0001。
关键数值与推荐
- 两类别模型与单类别模型比较p<0·001。
- 机械通气时间:表型2中位10·0天(IQR 6·3-21·0) vs 表型1中位6·6天(IQR 4·1-10·8),p<0·0001。
- 死亡率:表型2为13·8%(17/123) vs 表型1为2·2%(4/181),p=0·0001。
- 成人分类算法使用sTNFr1、血管活性药物使用和IL-6变量时AUC为0·956。
- 成人分类算法使用sTNFr1、血管活性药物使用和IL-8变量时AUC为0·954。
临床怎么用
- 临床中可依据炎症生物标志物、血管活性药物使用和脓毒症诊断识别高炎症型PARDS患儿。
- 高炎症型患儿机械通气时间更长、死亡风险更高,需加强监护和干预。
- 未来儿童ARDS临床试验应纳入表型分层分析。
局限性
- 本研究为二次分析,数据来源于RESTORE和BALI研究,可能存在选择偏倚。
- 样本量304例,结论需外部验证。
- 成人表型分类算法在儿童中的性能评估以潜在类别分析为金标准,尚需前瞻性验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Previous latent class analysis of adults with acute respiratory distress syndrome (ARDS) identified two phenotypes, distinguished by the degree of inflammation. We aimed to identify phenotypes in children with ARDS in whom developmental differences might be important, using a latent class analysis approach similar to that used in adults. METHODS: This study was a secondary analysis of data aggregated from the Randomized Evaluation of Sedation Titration for Respiratory Failure (RESTORE) clinical trial and the Genetic Variation and Biomarkers in Children with Acute Lung Injury (BALI) ancillary study. We used latent class analysis, which included demographic, clinical, and plasma biomarker variables, to identify paediatric ARDS (PARDS) phenotypes within a cohort of children included in the RESTORE and BALI studies. The association of phenotypes with clinically relevant outcomes and the performance of paediatric data in adult ARDS classification algorithms were also assessed. FINDINGS: 304 children with PARDS were included in this secondary analysis. Using latent class analysis, a two-class model was a better fit for the cohort than a one-class model (p<0·001). Latent class analysis identified two classes: class 1 (181 [60%] of 304 patients with PARDS) and class 2 (123 [40%] of 304 patients with PARDS), referred to as phenotype 1 and 2 hereafter. Phenotype 2 was characterised by higher concentrations of inflammatory biomarkers, a higher incidence of vasopressor use, and more frequent diagnosis of sepsis, consistent with the adult hyperinflammatory phenotype. All levels of severity of PARDS were observed across both phenotypes. Children with the hyperinflammatory phenotype (phenotype 2) had worse clinical outcomes than those with the hypoinflammatory phenotype (phenotype 1), with a longer duration of mechanical ventilation (median 10·0 days [IQR 6·3-21·0] for phenotype 2 vs 6·6 days [4·1-10·8] for phenotype 1, p<0·0001), and higher incidence of mortality (17 [13·8%] of 123 patients vs four [2·2%] of 181 patients, p=0·0001). When using adult phenotype classification algorithms in children, the soluble tumour necrosis factor receptor-1 (sTNFr1), vasopressor use, and interleukin (IL)-6 variables gave an area under the curve (AUC) of 0·956, and the sTNFr1, vasopressor use, and IL-8 variables gave an AUC of 0·954, compared with the gold standard of latent class analysis. INTERPRETATION: Latent class analysis identified two phenotypes in children with ARDS with characteristics similar to those in adults, including worse outcomes among patients with the hyperinflammatory phenotype. PARDS phenotypes should be considered in design and analysis of future clinical trials in children. FUNDING: US National Institutes of Health.
引用
- Dahmer MK, Yang G, Zhang M, et al. Identification of phenotypes in paediatric patients with acute respiratory distress syndrome: a latent class analysis. Lancet Respir Med. 2021. PMID: 34883088. doi:10.1016/S2213-2600(21)00382-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。